Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of HER2-Positive Breast Cancer
1.2 Key Market Segments
1.2.1 HER2-Positive Breast Cancer Segment by Type
1.2.2 HER2-Positive Breast Cancer Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 HER2-Positive Breast Cancer Market Overview
2.1 Global Market Overview
2.1.1 Global HER2-Positive Breast Cancer Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global HER2-Positive Breast Cancer Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 HER2-Positive Breast Cancer Market Competitive Landscape
3.1 Global HER2-Positive Breast Cancer Sales by Manufacturers (2019-2024)
3.2 Global HER2-Positive Breast Cancer Revenue Market Share by Manufacturers (2019-2024)
3.3 HER2-Positive Breast Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global HER2-Positive Breast Cancer Average Price by Manufacturers (2019-2024)
3.5 Manufacturers HER2-Positive Breast Cancer Sales Sites, Area Served, Product Type
3.6 HER2-Positive Breast Cancer Market Competitive Situation and Trends
3.6.1 HER2-Positive Breast Cancer Market Concentration Rate
3.6.2 Global 5 and 10 Largest HER2-Positive Breast Cancer Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 HER2-Positive Breast Cancer Industry Chain Analysis
4.1 HER2-Positive Breast Cancer Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of HER2-Positive Breast Cancer Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 HER2-Positive Breast Cancer Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global HER2-Positive Breast Cancer Sales Market Share by Type (2019-2024)
6.3 Global HER2-Positive Breast Cancer Market Size Market Share by Type (2019-2024)
6.4 Global HER2-Positive Breast Cancer Price by Type (2019-2024)
7 HER2-Positive Breast Cancer Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global HER2-Positive Breast Cancer Market Sales by Application (2019-2024)
7.3 Global HER2-Positive Breast Cancer Market Size (M USD) by Application (2019-2024)
7.4 Global HER2-Positive Breast Cancer Sales Growth Rate by Application (2019-2024)
8 HER2-Positive Breast Cancer Market Segmentation by Region
8.1 Global HER2-Positive Breast Cancer Sales by Region
8.1.1 Global HER2-Positive Breast Cancer Sales by Region
8.1.2 Global HER2-Positive Breast Cancer Sales Market Share by Region
8.2 North America
8.2.1 North America HER2-Positive Breast Cancer Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe HER2-Positive Breast Cancer Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific HER2-Positive Breast Cancer Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America HER2-Positive Breast Cancer Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa HER2-Positive Breast Cancer Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Pfizer (Pharmacia and Upjohn Company)
9.1.1 Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Basic Information
9.1.2 Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Product Overview
9.1.3 Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer Product Market Performance
9.1.4 Pfizer (Pharmacia and Upjohn Company) Business Overview
9.1.5 Pfizer (Pharmacia and Upjohn Company) HER2-Positive Breast Cancer SWOT Analysis
9.1.6 Pfizer (Pharmacia and Upjohn Company) Recent Developments
9.2 Novartis
9.2.1 Novartis HER2-Positive Breast Cancer Basic Information
9.2.2 Novartis HER2-Positive Breast Cancer Product Overview
9.2.3 Novartis HER2-Positive Breast Cancer Product Market Performance
9.2.4 Novartis Business Overview
9.2.5 Novartis HER2-Positive Breast Cancer SWOT Analysis
9.2.6 Novartis Recent Developments
9.3 AstraZeneca Pharmaceuticals
9.3.1 AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Basic Information
9.3.2 AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Product Overview
9.3.3 AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer Product Market Performance
9.3.4 AstraZeneca Pharmaceuticals HER2-Positive Breast Cancer SWOT Analysis
9.3.5 AstraZeneca Pharmaceuticals Business Overview
9.3.6 AstraZeneca Pharmaceuticals Recent Developments
9.4 Eli Lilly
9.4.1 Eli Lilly HER2-Positive Breast Cancer Basic Information
9.4.2 Eli Lilly HER2-Positive Breast Cancer Product Overview
9.4.3 Eli Lilly HER2-Positive Breast Cancer Product Market Performance
9.4.4 Eli Lilly Business Overview
9.4.5 Eli Lilly Recent Developments
9.5 Roche Group
9.5.1 Roche Group HER2-Positive Breast Cancer Basic Information
9.5.2 Roche Group HER2-Positive Breast Cancer Product Overview
9.5.3 Roche Group HER2-Positive Breast Cancer Product Market Performance
9.5.4 Roche Group Business Overview
9.5.5 Roche Group Recent Developments
9.6 Merck
9.6.1 Merck HER2-Positive Breast Cancer Basic Information
9.6.2 Merck HER2-Positive Breast Cancer Product Overview
9.6.3 Merck HER2-Positive Breast Cancer Product Market Performance
9.6.4 Merck Business Overview
9.6.5 Merck Recent Developments
9.7 Jiangsu HengRui Medicine
9.7.1 Jiangsu HengRui Medicine HER2-Positive Breast Cancer Basic Information
9.7.2 Jiangsu HengRui Medicine HER2-Positive Breast Cancer Product Overview
9.7.3 Jiangsu HengRui Medicine HER2-Positive Breast Cancer Product Market Performance
9.7.4 Jiangsu HengRui Medicine Business Overview
9.7.5 Jiangsu HengRui Medicine Recent Developments
9.8 Odonate Therapeutics
9.8.1 Odonate Therapeutics HER2-Positive Breast Cancer Basic Information
9.8.2 Odonate Therapeutics HER2-Positive Breast Cancer Product Overview
9.8.3 Odonate Therapeutics HER2-Positive Breast Cancer Product Market Performance
9.8.4 Odonate Therapeutics Business Overview
9.8.5 Odonate Therapeutics Recent Developments
9.9 Radius Pharmaceuticals
9.9.1 Radius Pharmaceuticals HER2-Positive Breast Cancer Basic Information
9.9.2 Radius Pharmaceuticals HER2-Positive Breast Cancer Product Overview
9.9.3 Radius Pharmaceuticals HER2-Positive Breast Cancer Product Market Performance
9.9.4 Radius Pharmaceuticals Business Overview
9.9.5 Radius Pharmaceuticals Recent Developments
9.10 Immunomedics
9.10.1 Immunomedics HER2-Positive Breast Cancer Basic Information
9.10.2 Immunomedics HER2-Positive Breast Cancer Product Overview
9.10.3 Immunomedics HER2-Positive Breast Cancer Product Market Performance
9.10.4 Immunomedics Business Overview
9.10.5 Immunomedics Recent Developments
9.11 Syndax Pharmaceuticals
9.11.1 Syndax Pharmaceuticals HER2-Positive Breast Cancer Basic Information
9.11.2 Syndax Pharmaceuticals HER2-Positive Breast Cancer Product Overview
9.11.3 Syndax Pharmaceuticals HER2-Positive Breast Cancer Product Market Performance
9.11.4 Syndax Pharmaceuticals Business Overview
9.11.5 Syndax Pharmaceuticals Recent Developments
9.12 Bayer
9.12.1 Bayer HER2-Positive Breast Cancer Basic Information
9.12.2 Bayer HER2-Positive Breast Cancer Product Overview
9.12.3 Bayer HER2-Positive Breast Cancer Product Market Performance
9.12.4 Bayer Business Overview
9.12.5 Bayer Recent Developments
9.13 Eagle Pharmaceuticals
9.13.1 Eagle Pharmaceuticals HER2-Positive Breast Cancer Basic Information
9.13.2 Eagle Pharmaceuticals HER2-Positive Breast Cancer Product Overview
9.13.3 Eagle Pharmaceuticals HER2-Positive Breast Cancer Product Market Performance
9.13.4 Eagle Pharmaceuticals Business Overview
9.13.5 Eagle Pharmaceuticals Recent Developments
9.14 Merrimack Pharmaceuticals
9.14.1 Merrimack Pharmaceuticals HER2-Positive Breast Cancer Basic Information
9.14.2 Merrimack Pharmaceuticals HER2-Positive Breast Cancer Product Overview
9.14.3 Merrimack Pharmaceuticals HER2-Positive Breast Cancer Product Market Performance
9.14.4 Merrimack Pharmaceuticals Business Overview
9.14.5 Merrimack Pharmaceuticals Recent Developments
9.15 GlaxoSmithKline
9.15.1 GlaxoSmithKline HER2-Positive Breast Cancer Basic Information
9.15.2 GlaxoSmithKline HER2-Positive Breast Cancer Product Overview
9.15.3 GlaxoSmithKline HER2-Positive Breast Cancer Product Market Performance
9.15.4 GlaxoSmithKline Business Overview
9.15.5 GlaxoSmithKline Recent Developments
9.16 Millennium Pharmaceuticals
9.16.1 Millennium Pharmaceuticals HER2-Positive Breast Cancer Basic Information
9.16.2 Millennium Pharmaceuticals HER2-Positive Breast Cancer Product Overview
9.16.3 Millennium Pharmaceuticals HER2-Positive Breast Cancer Product Market Performance
9.16.4 Millennium Pharmaceuticals Business Overview
9.16.5 Millennium Pharmaceuticals Recent Developments
10 HER2-Positive Breast Cancer Market Forecast by Region
10.1 Global HER2-Positive Breast Cancer Market Size Forecast
10.2 Global HER2-Positive Breast Cancer Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe HER2-Positive Breast Cancer Market Size Forecast by Country
10.2.3 Asia Pacific HER2-Positive Breast Cancer Market Size Forecast by Region
10.2.4 South America HER2-Positive Breast Cancer Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of HER2-Positive Breast Cancer by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global HER2-Positive Breast Cancer Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of HER2-Positive Breast Cancer by Type (2025-2030)
11.1.2 Global HER2-Positive Breast Cancer Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of HER2-Positive Breast Cancer by Type (2025-2030)
11.2 Global HER2-Positive Breast Cancer Market Forecast by Application (2025-2030)
11.2.1 Global HER2-Positive Breast Cancer Sales (K Units) Forecast by Application
11.2.2 Global HER2-Positive Breast Cancer Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings
